Citi raised the firm’s price target on Applied Therapeutics to $8 from $7 and keeps a Buy rating on the shares. The analyst updated models in Smid-cap biotechnology following the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics management to meet virtually with William Blair
- Applied Therapeutics reports Q2 EPS (13c), consensus (16c)
- Applied Therapeutics Reports Second Quarter 2024 Financial Results
- McDonald’s downgraded, PayPal upgraded: Wall Street’s top analyst calls
- Applied Therapeutics initiated with an Outperform at William Blair